Difficult week in Wilmington

[Anonymous]

What group will be effected?

Good question. I thought all the layoffs happened in January, effective 3/30/12. Haven't heard a owrd about this. Probably all BS.

 

[Anonymous]

Why you ask? Because nothing is going to happen that's why! Just more rumor here on CP based on 0 facts. AZ is flush with cash. Why do you think don't care if we work half days? They have so much cash, they don't need to worry about such things!

Right, more rumors! Why don't you take your head out of your ass; a whole bunch of people in study delivery and ops are leaving this week. And after tomorrow, there should be a whole lot more, but this time from all over the company.

 

[Anonymous]

More victims of the AZ regime. Will anyone be left after the next hit?

 

[Anonymous]

40% of HR laid off

 

[Anonymous]

40% of HR laid off

Hope so!!!

 

[Anonymous]

40% of HR laid off

Starting with your lazy ass. Dipshit.

 

[Anonymous]

Good Luck to all the poor souls being exited tomorrow from Wilmington HQ. There is life after AZ and it will be just fine. You will find your way in time.

 

[Anonymous]

Good Luck to all the poor souls being exited tomorrow from Wilmington HQ. There is life after AZ and it will be just fine. You will find your way in time.

Yea, maybe we can go work for Sanofi, Merck or Roche?!

Yippe~

 

[Anonymous]

Looking over today's financial results for 2Q and YTD, I see where AZ is down 20% in US for sales for 6 months 2012. AZ worldwide is down 15%. Total revenue is down almost 3 Billion dollars compared to June 2011. Where is Senior Leadership planning to make up that difference? Seroquel's generic hit is major. Brillanta only did $3M so far since launch? Vimovo did $15M? Wow!

 

[Anonymous]

If they can't make up the difference on the top line they do it on the bottom line, which mens you're history.

 

[Anonymous]

Looking over today's financial results for 2Q and YTD, I see where AZ is down 20% in US for sales for 6 months 2012. AZ worldwide is down 15%. Total revenue is down almost 3 Billion dollars compared to June 2011. Where is Senior Leadership planning to make up that difference? Seroquel's generic hit is major. Brillanta only did $3M so far since launch? Vimovo did $15M? Wow!

you do realize they were expecting a hit at seroquel. I'm pretty sure they weren't thinking they were going to gain from a generic.

 

[Anonymous]

you do realize they were expecting a hit at seroquel. I'm pretty sure they weren't thinking they were going to gain from a generic.

It isn't just Seroquel. If you read the earnings you will see that Crestor sales are now falling too due to the impact generic Lipitor. That fall will now accelerate as all new patients will be started on the generic and only be offered Crestor if they fail to meet goal or if they have an adverse reaction to Lipitor. Lipitor was not significantly different in performance compared to Crestor, so that isn't going to very leave much. The remaining years left of patent exclusivity for Crestor till 2016 will not lead to the Crestor sales they had hoped. Nexium had already started to tank last year for the same reason, generic competition of patent expired competitor products. None of the new products in the "pipeline" can even begin to make a dent in these deficits.
Look for a lot more cost cutting. What else can they do? When will it be announced? Probably soon after the permanent CEO is announced in the fall. The Europeans are all going on long vacations now, so it will have to wait till then.

 

[Anonymous]

Crestor sales were down 5% in the quarter, largely due to the loss of exclusivity in Canada and Brazil. Sales in the U.S. were down 1%.

That's right, down 1% in the U.S.

 

[Anonymous]

Back in 2008, AZ cut 50% of both Respiratory and Oncology. In 2009 they cut around 10% of MC1. Lots of good people let go. Looking at 2009 year end report, AZ was +4% in world wide sales, yet over a 1,000 were let go (just in the field, not including HQ). If people don't see the writing on the wall after today's report, their head is still in the sand.

 

[Anonymous]

Crestor sales were down 5% in the quarter, largely due to the loss of exclusivity in Canada and Brazil. Sales in the U.S. were down 1%.

That's right, down 1% in the U.S.

Sales of Crestor in U.S was close to 800 million for second quarter. So still bringing in around $3 billion per year.

That will remain stable or increase through 2016. Sorry bout your luck.

 

[Anonymous]

Sales of Crestor in U.S was close to 800 million for second quarter. So still bringing in around $3 billion per year.

That will remain stable or increase through 2016. Sorry bout your luck.

Are you serious??? Increase, hey jack look at what happened to Nexium, Toprol XL, Seroquel when a generic was introduced. Take your increase and put a pool or addition on your home, good luck paying it off with 2 jobs, no offense. AZ was able to absorb the decline in dollar volume with Nexium and Toprol XL via Crestor and Seroquel. Now that they are victims of generics, AZ has nothing to cushion those new lack of sales. Follow?

 

[Anonymous]

Are you serious??? Increase, hey jack look at what happened to Nexium, Toprol XL, Seroquel when a generic was introduced. Take your increase and put a pool or addition on your home, good luck paying it off with 2 jobs, no offense. AZ was able to absorb the decline in dollar volume with Nexium and Toprol XL via Crestor and Seroquel. Now that they are victims of generics, AZ has nothing to cushion those new lack of sales. Follow?

Did you not read the earnings transcript? Crestor is a little different.
Not sure what you mean about home improvements or pools, and no offense taken.


"Sales in the U.S. were down 1%. Crestor total prescriptions in the U.S. are still growing ahead of the statin market, and the performance has been quite stable in the face of generic atorvastatin. As we have mentioned many times, 94% of Crestor volumes come from continued therapy, which we expect it would remain stable, and that's been the case. We've also seen a stable trend in net dynamic volume. That is new starts and switches to Crestor minus switches from Crestor. And that's holding steady even since the launch of multisource of atorvastatin products at end of May. We're also seeing a steady improvement in the volume of patients switching from Crestor since the initial bump from the atorvastatin launch. And that's not by accident. It's the result of considerable work to position Crestor in the market as the preferred statin for patients to increase cardiovascular risk, a position that has helped support usage of the product in a highly genericized statin market."

 

[Anonymous]

What none of you idiots on here seem to realize is that core operating profit is falling like a rock! PROFIT IS WHAT MATTERS MORONS!

 

[Anonymous]

Back in 2008, AZ cut 50% of both Respiratory and Oncology. In 2009 they cut around 10% of MC1. Lots of good people let go. Looking at 2009 year end report, AZ was +4% in world wide sales, yet over a 1,000 were let go (just in the field, not including HQ). If people don't see the writing on the wall after today's report, their head is still in the sand.

. We create a headroom to make those investments by our restructuring and reshaping efforts. We're certainly looking to achieve a net reduction in spend, but we are absolutely focused on preserving our commercial capabilities and capacity to drive performance where we can make a difference. That means reducing noncustomer-facing positions, and consolidation of our regional headquarter structure is a key component of that. In fact, around 40% of the headcount reduction in sales and marketing related to our previously announced restructuring program will be noncustomer-facing positions. We are evolving the size and deployment of our field force to match the evolving product portfolio with a general move towards reductions into more mature, developed markets while investing in emerging markets. Where we reduce our sales force, we're building up our headcount in new channels like service teams and call centers. Along with digital, with these new channels, we're maintaining, and in some cases, increasing market share for our brands at a lower cost than the traditional sales-rep-only model.
What a genius!

 

[Anonymous]

40% of HR laid off

Only 60% to go.